Zenas BioPharma, Inc. (ZBIO)
$26.40-3.15%Close
SELLCRISIS · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.7B
- Beta
- -1.02
- P/E (TTM)
- -2.62
- Short % float
- 114.11%
- Days to cover
- 15.5
- SI change
- +0.6%
- 1W
- -6.61%
- 1M
- -21.15%
- vs SPY 1W
- -7.03%
- vs SPY 1M
- -23.21%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-113.8%
REV YoY-
ROE-189.7%
EPS YoY-
ROA-69.0%
GROSS-5973
OP-47557
NET-48438
[VALUATION]
P/E TTM-2.62
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B6.43
P/FCF-
EV/EBITDA-3.90
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E157.67
ALTMAN Z-
CURR RATIO9.93
ND/EBITDA-
BETA-1.02
Company news
FAQ
- What is LOPJLB’s current signal on ZBIO?
- LOPJLB’s latest quantitative signal on Zenas BioPharma, Inc. (ZBIO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ZBIO in?
- Zenas BioPharma, Inc. (ZBIO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Zenas BioPharma, Inc. (ZBIO) do?
- Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus…